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Human mesenchymal stem/progenitor cells (hMSCs) from bone
marrow and other tissues are currently being administered to large
numbers of patients even though there are no biomarkers that
accurately predict their efficacy in vivo. Using a mouse model of
chemical injury of the cornea, we found that bone-marrow–derived
hMSCs isolated from different donors varied widely in their efficacy
in modulating sterile inflammation. Importantly, RT-PCR assays of
hMSCs for the inflammation-modulating protein TSG-6 expressed
by the TNFα-stimulated gene 6 (TSG-6 or TNFAIP6) predicted their
efficacy in sterile inflammation models for corneal injury, sterile
peritonitis, and bleomycin-induced lung injury. In contrast, the
levels of TSG-6 mRNA were negatively correlated with their po-
tential for osteogenic differentiation in vitro and poorly correlated
with other criteria for evaluating hMSCs. Also, a survey of a small
cohort suggested that hMSCs from female donors compared with
male donors more effectively suppressed sterile inflammation, ex-
pressed higher levels of TSG-6, and had slightly less osteogenic
potential.
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Human mesenchymal stem/progenitor cells (hMSCs) frombone marrow, adipose tissues, placenta, umbilical cord, and
other tissues are currently being administered to large numbers
of patients. Over 80 clinical trials with hMSCs have been regis-
tered (clinicaltrials.gov), and 5 have reached the Phase II or III
stage of development (1). The trials are proceeding even though
cultures of the cells are heterogeneous, and there is large
variability in quality of hMSCs dependent on conditions, such as
differences among donors, conditions used to expand the cells in
culture, and random sampling in harvesting the cells from bone
marrow and other tissues (2–5). Accounting for the variability
among preparations is confounded by the lack of definitive
markers for the cells. In addition, there are no biomarkers to
predict the efficacy of hMSC samples in vivo. Therefore, the
value of the data obtained from different clinical trials may well
be compromised by variations in the quality of the hMSCs used.
Recent data suggest that the therapeutic effects of the cells
were explained in part by their paracrine effects, such as ex-
pression of factors that modulate inflammatory and immune
responses, that limit growth of cancers, or that enhance tissue
repair (2, 6–8). We recently observed that i.v.-infused hMSCs
modulated excessive sterile inflammation and thereby improved
mouse models for myocardial infarction (9), corneal injury (10),
or peritonitis (11), in part because the hMSCs were activated to
secrete TNFα-stimulated gene 6 (TSG-6), a protein that is a
natural modulator of inflammation (12–14). Of special interest
was that a well-known model of chemical injury of the cornea
made it possible to obtain quantitative dose–response data for
the effectiveness of recombinant TSG-6 on both neutrophil in-
filtration and the functional integrity of the tissue (15). Using this
model and two other models for sterile inflammation, here, we
demonstrated that bone-marrow–derived hMSCs isolated from
different donors showed wide variations in their efficacy in
modulating inflammation. Also, we identified a biomarker of
mRNA levels for TSG-6 that predicts the in vivo efficacy of dif-
ferent donor-derived hMSCs in suppressing inflammation. The
biomarker should prove useful in selecting preparations of hMSCs
for therapy of patients.
Results
We previously demonstrated (10) that, after ethanol injury and
scraping of the cornea, i.v. infusion of bone-marrow hMSCs
decreased sterile inflammation and thereby decreased opacity of
the tissue. The hMSCs were effective even though quantitative
PCR assays of mRNA for human GAPDH indicated that few if
any of the cells reached the cornea after i.v. infusion of 10 mil-
lion hMSCs in a similar rat model of ethanol injury of the cornea
(10). As indicated in Fig. 1A, the decrease in opacity was pro-
portional to the decrease in the cornea of myeloperoxidase (MPO),
a semiquantitative measure of activated neutrophils. We used the
same model to compare the efficacy of different preparations of
hMSCs, here defined by the donors who provided the bone-mar-
row aspirates and expanded under essentially the same conditions,
and found that they varied in their efficacy in suppressing opacity
and MPO levels (Fig. 1 B and C). Some MSC preparations (from
donors 235, 6015, and 269 of marrow aspirates) were highly ef-
fective, preventing opacity and decreasing MPO, and others
(donors 7052, 7074, and 7075) provided little protection.
To identify a biomarker that predicted efficacy of hMSCs in
the model, we assayed the same cells with conventional assays
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used to characterize MSCs in culture (16, 17). Surprisingly, there
were no significant correlations with the efficacy of the cells in
suppressing MPO in the model (Fig. 2A). In fact, there was
a negative correlation with the potential of the hMSCs for os-
teogenic differentiation in vitro (Fig. 2A). Also, there was no
significant correlation with adipogenic potential, rate of pro-
liferation, and colony forming units-fibroblastoid (CFU-f). Sim-
ilarly, there was no apparent relationship to the spindle-shaped
morphology of cells (Fig. S1) that has been used to identify early
progenitors in the cultures (18, 19), and there were no significant
differences in expression of standard surface markers between
the effective and ineffective hMSCs (Table S1).
To search further for informative biomarkers, we performed
RT-PCR assays on the hMSCs for the expression of genes that
have been suggested as responsible for anti-inflammation and
immune-suppressive effects of hMSCs (6, 9–11, 20–24). As ex-
pected from previous observations in the cornea model (10, 15),
there was a highly significant correlation between the levels of
mRNA for TSG-6 in the hMSCs and their efficacy in reducing
MPO levels in the cornea model (Fig. 2B). The correlation was
essentially the same if based on assays of hMSCs that were freshly
isolated from culture or on assays of the same cells after ex-
pression of TSG-6 was increased by incubation with TNF-α for
16 h (9). There was a less-significant positive correlation with the
levels of heme oxygenase 1 (HMOX1) in hMSCs that were freshly
isolated from culture, but no significant correlation with hMSCs
that were incubated with TNF-α. In addition, there were no sig-
nificant correlations with the levels of mRNA for cyclooxygenase
2 (COX2), a key enzyme of synthesis of Prostaglandin E2, IL-1
receptor antagonist (IL-1Ra), transforming growth factor-β1
(TGF-β1), or indoleamine 2,3-dioxygenase 1 (IDO1).
The role of TSG-6 in the efficacy of the cells was confirmed
by experiments (Fig. 3) in which TSG-6 was overexpressed in
hMSCs that initially expressed a low level of TSG-6 (donor
7052). Overexpression of TSG-6 decreased the potential of the
cells to differentiate to mineralizing cells (Fig. 3B) and increased
the efficacy of the hMSCs in the model for injury of the cornea
(Fig. 3 C–E).
However, as hMSCs expressing high levels of TSG-6 were ex-
panded, there was a marked decrease in expression of TSG-6
between 10 and 20 population doublings (Fig. S2). The results
were consistent with previous observations that cultures of
hMSCs lose many of their biological properties as they are ex-
panded beyond about 20 population doublings in culture (17, 25).
To evaluate further the predictive value of TSG-6 expression
as a biomarker, we compared the efficacy of the hMSCs in two
additional murine models: sterile inflammation of the perito-
neum induced by zymosan (11) and lung injury induced by
bleomycin (26). We tested six different donor preparations of
hMSCs (Fig. 4A): three with the highest levels of TSG-6 ex-
pression (defined as TSG-6hi hMSCs) and three with the lowest
levels (defined as TSG-6low hMSCs). The efficacy of each of the
six samples was then tested separately in the models.
As expected, the three preparations of TSG-6hi hMSCs were
more effective than the three preparations of TSG-6low hMSCs
in preventing opacity and decreasing MPO in the cornea model
A B
C
Fig. 1. hMSCs from different donors exhibit variations in therapeutic effi-
cacy in suppressing sterile inflammation in the chemical burn-injured cornea.
(A) Correlation between opacity grades and myeloperoxidase (MPO) levels in
the cornea 3 d after ethanol injury and scraping of the epithelium. The
values were data from 15mice that were each treated with different numbers
of hMSCs (0.01–1 × 106 cells) from donor 6015 or HBSS. (B) Representative
corneal photographs on day 7 after injury and i.v. administration of vehicle
(HBSS 1) or 1 × 106 hMSCs from different donors of bone-marrow aspirates.
(C) Inflammation of the cornea as measured by MPO levels in the cornea on
day 1 after injury. Values are means ± SD (n = 3–5 for each of 13 donor
hMSCs; n = 6 for HBSS, *P < 0.05; **P < 0.01; ***P < 0.001; N.S., no signif-
icant difference; assessed by one-way ANOVA with Dunnett’s multiple
comparison test).
A
B Fig. 2. Correlation between potential biomarkers
and effectiveness in reducing MPO levels in the
injured cornea. (A) Correlations between efficacy
of hMSCs in reducing MPO levels in the cornea
model and conventional assays in vitro for MSCs.
(B) Correlations between efficacy of hMSCs in re-
ducing MPO levels in the cornea model and ex-
pression by RT-PCR of genes previously linked to
the therapeutic benefits of hMSCs. (Upper and
Lower) Values obtained with (Lower) or without
(Upper) stimulation of the cells with TNF-α. IDO1
was not detected in some hMSCs that were not
stimulated with TNF-α.
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(Fig. 4 B and C). They were also more effective in reducing
proinflammatory cytokines in the peritonitis model (Fig. 4D). In
addition, in the bleomycin model for lung injury, in which fibrosis
is detected by histology at 8 d (26), they were more effective in
improving survival (Fig. 4E) and preserving body weight (Fig.
S3A) in the treated mice compared with a control group. However,
the differences in survival between mice that received TSG-6hi
hMSCs and TSG-6low hMSCs were not significant because one
(donors 265 and 7075) of each group showed moderate survival
(Fig. S3B).
The negative correlation between efficacy in the cornea model
and osteogenic potential of the hMSCs (Fig. 2A) raised the
possibility that efficacy of the cells was linked to increased
NF-κB signaling because a recent report indicated that increased
NF-κB signaling inhibited osteogenesis (27). As expected, there
was a negative correlation between osteogenic potential and
expression of TSG-6 in the hMSCs (Fig. 5A). Also, there was
a weak correlation between expression of TSG-6 and expression
of TNFRSF1A, a tumor necrosis factor receptor superfamily
member 1A, that may reflect the potential of TNF-α and other
proinflammatory factors to up-regulate expression of TSG-6
(28). More importantly, NF-κB binding activity was higher in
hMSCs expressing high levels of TSG-6 (Fig. 5C), and inhibition
of NF-κB signaling with SN50 (29) both decreased expression of
TSG-6 (Fig. 5D) and increased osteogenic differentiation of
hMSCs in culture (Fig. 5 E and F).
To search for additional useful markers for hMSCs, we tested
for correlations with the anonymous personal data available on
the donors of the bone-marrow aspirates from which the hMSCs
were obtained. Of special interest was that, in the small cohort
available, expression of TSG-6 has higher in hMSCs from female
donors, especially after the cells were stimulated with TNF-α
(Fig. 6A). Also, as expected, hMSCs from the female donors
were more effective in suppressing MPO levels in the cornea
model and had slightly less osteogenic potential in culture (Fig.
6B). There were negative correlations with height and weight
A
C D E
B
Fig. 3. Overexpression of TSG-6 in hMSCs decreases osteogenic capacity in
vitro and increases anti-inflammatory effects in vivo. (A) Real-time RT-PCR
for the levels of TSG-6 in hMSCs (donor 7052) transfected with control vector
(7052Δcont) or TSG-6 construct (7052ΔTSG-6) after 24 h. Values are means ± SD.
(B) Representative photos of cultures of hMSCs stained with Alizarin Red
after osteogenic differentiation. (C) Photographs of corneas of mice that
received i.v. injections of 1 × 106 cells of 7052Δcont or 7052ΔTSG-6 after ethanol
injury to cornea. (D) Quantification of corneal opacity on day 3 using clinical
grading system on a 0–4 scale (n = 7 or 8 mice for each group, **P < 0.01;
***P < 0.001; N.S., no significant difference; data evaluated by one-way
ANOVA). (E) Inflammation of the cornea as assayed by MPO levels 1 d after
the injury. The 7052 control MSCs were more effective in suppressing MPO
levels than in Fig. 1C, apparently because transfection with control vector
itself increased expression of TSG-6 (not shown) (n = 6–8 for each group,
*P < 0.05, **P < 0.01, ***P < 0.001; assessed by one-way ANOVA).
A
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C
Fig. 4. The TSG-6hi hMSCs are more effective in suppressing sterile in-
flammation in three in vivo models. (A) RT-PCR assays for TSG-6 expression in
hMSCs from a series of donors of bone-marrow aspirates with and without
TNF-α stimulation. Values are relative to express level in donor 7075 that was
set as 1.0. To simplify comparisons of the data from experiments in vivo,
three preparations with the highest levels were designated as TSG-6hi, and
three with the lowest levels were designated as TSG-6low. (B) Opacity of the
cornea on day 7 after ethanol injury. The values are data from three to five
mice that were each treated with hMSCs from the same six donors, of which
three were TSG-6hi hMSCs and three were TSG-6low hMSCs (***P < 0.001; N.S.,
no significant difference; assessed by one-way ANOVA). (C) Inflammation
of the cornea 1 d after injury as assayed by MPO levels. (n = 4 or 5 mice that
were treated with hMSCs from the same donor and n = 12 for HBSS control;
**P < 0.01, ***P < 0.001; assessed by one-way ANOVA). (D) Assays of the
efficacy of the hMSCs in the mouse model for zymosan-induced peritonitis.
Values are from ELISAs for mouse TNF-α, CXCL1, and CXCL2 in peritoneal
lavage collected 4 h after i.p. injection of zymosan followed by injection of
1.5 × 106 hMSCs (n = 3 mice treated with the same donor MSCs and n = 7 for
HBSS control; *P < 0.05, **P < 0.01, ***P < 0.001; N.S., no significant dif-
ference; assessed by one-way ANOVA). (E) Survival proportions after bleo-
mycin injury of lung in mice followed by i.v. administration of 2.5 × 105
hMSCs [n = 5 or 6 mice treated with hMSCs from the same of six donors and
n = 15 for HBSS controls; assessed by log-rank (Mantel-Cox) test].
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(Fig. 6C), but no correlation with age in the small cohort that was
clustered in the younger ages (Fig. 6C). Adjusting for height and
weight via a body mass index, analyses of the data with three
subsequent multiple linear-regression models incorporating all
of the above measures indicated that the most parsimonious
models for TSG-6 levels in hMSCs (with and without TNF-α
stimulation) included a sex coefficient as the common predictive
item. The MPO-level difference between females and males is
highly significant (P = 0.0009); the 95% confidence interval for
this difference indicated that male donors showed decreases in
MPO levels that ranged from 7.06% to 40.07%, compared with
female donors.
We also detected a negative correlation between date of col-
lection of the bone-marrow aspirates from which hMSCs were
immediately prepared and the efficacy of the cells in the cornea
model (Fig. S4): i.e., the older samples were more efficacious.
This correlation was probably explained by the fact that most of
the older samples were from female donors and the more recent
from male donors (Table S2).
To explore further the apparent sex bias, we examined the
effects of incubating hMSCs with estradiol, the female hormone
that reaches the highest peak values in serum (up to 1.6 nM)
during the menstrual cycle (30). One-day exposure of hMSCs to
low doses (10–100 pM) of estradiol decreased TSG-6 levels in
hMSCs whereas a high dose (100 nM) of estradiol increased
TSG-6 expression in hMSCs (Fig. S5A). The effects of the high
dose persisted after incubation with 100 nM for 2 d, in that the
increased levels of TSG-6 mRNA were observed after the cells
were incubated without estradiol for an additional 2 d (Fig. S5B).
Furthermore, pretreatment of low doses of estradiol in hMSCs
for 4 d promoted osteogenic differentiation whereas pretreatment
with a high dose of 400 nM for 4 d suppressed osteogenic dif-
ferentiation (Fig. S5 D and E), without affecting cell viability
(Fig. S5C).
Discussion
The results presented here may overcome a major barrier to
research with hMSCs: they provide, to our knowledge, the first
biomarker that can predict the efficacy of the human cells in
reducing sterile inflammation in in vivo models. Assays in the
model for ethanol injury of the cornea demonstrated marked
differences in the inflammation-suppressive efficacy of different
preparations of hMSCs. The efficacy of the hMSCs, in turn, was
proportional to their mRNA levels for the inflammation-modu-
lating protein TSG-6. The levels of TSG-6 expression predicted
the efficacy of the cells not only in the model for chemical injury
of the cornea but also for sterile inflammation produced by i.p.
injection of the yeast extract zymosan in mice and, with some-
what less accuracy, in a more complex murine model of bleo-
mycin-induced lung injury. The more variable results in the
bleomycin model probably reflect the complexity of this model in
which bleomycin triggers apoptosis and releases oxidants, and
this injury followed first by a phase marked by invasion of in-
flammatory and immune cells and then by a fibrotic phase (31).
The RT-PCR assay for TSG-6 expression that was used
is robust, and it can be performed in about 4 h. As reported
A B C
D E F
Fig. 5. Negative correlation between osteogenic differentiation potential
and increased NF-κB signaling. (A) Correlation between osteogenic differ-
entiation potential in vitro and the levels of mRNA for TSG-6 in hMSCs after
stimulation with 5 ng/mL TNF-α stimulation for 16 h. (B) Correlation between
the levels of mRNA for TSG-6 and TNFRSF1A in hMSCs. (C) Nuclear extracts
from TSG-6hi and TSG-6low hMSCs were assayed for NF-κB DNA-binding ac-
tivity by EMSA. The specific DNA-binding activity of NF-κB complex is in-
dicated by an arrow. (D) Real-time RT-PCR for the levels of TSG-6 in hMSCs
(TSG-6hi donor 6015) after 24-h treatment of SN50, an inhibitor of NF-κB
signaling. Values are means ± SD. (E) Representative photo of cultures of
TSG-6hi hMSCs (donor 6015) treated with SN50, incubated in osteogenic
medium, and stained with Alizarin Red. (F) Quantification of Alizarin Red
staining of cultures treated as in E. Values are means ± SD (n = 3; ***P <
0.001; assessed by one-way ANOVA).
A
C
B
Fig. 6. Correlations with sex and other variables. (A)
RT-PCR assays of TSG-6 in hMSCs from male and fe-
male donors of bone-marrow aspirates, with and
without stimulation of the cells with TNF-α. (B) Com-
parison of hMSCs from male and female donors in
reducing MPO in the model for ethanol injury of the
cornea and in osteogenic potential in vitro. (C) Cor-
relation of the efficacy of hMSCs in reducing MPO
in the cornea model with height, weight, and age
of donors.
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previously (9), there was a close correlation between levels of
mRNA for TSG-6 in MSCs and secretion of the protein in naive
hMSCs, hMSCs stimulated with TNF-α, and knock-down experi-
ments with siRNAs. Therefore, the levels of TSG-6 expression
with this assay, or some modified assay for TSG-6 expression,
should be useful in selecting hMSCs to reduce the variability in
experiments and clinical trials with MSCs for the large number of
diseases in which sterile inflammation is now recognized to play
a critical role (3, 9, 32, 33). hMSCs, however, are highly sensitive
to their microenvironments (3, 4, 9, 17, 25), and the levels of
TSG-6 in a given preparation of MSCs may vary under different
culture conditions to prepare the cells before administration in vivo.
One of the critical observations was that the conventional
assays used to characterize hMSCs did not predict the efficacy of
the cells in suppressing inflammation in vivo. Also, with the ex-
ception of heme oxygenase 1, there was no significant correlation
with expression of several other genes previously linked to the
therapeutic potentials of the cells (6, 9–11, 20–24). Of special
interest was the negative correlation between the effectiveness of
the cells in suppressing inflammation in the cornea model and
their potential for osteogenic differentiation in culture because
this negative correlation was linked to increased NF-κB signaling
in the more efficacious cells and provided an independent
marker for such cells. Also, the negative correlation with osteo-
genic differentiation suggests that hMSCs optimal for one appli-
cation, such as suppression of inflammation, may be suboptimal
for other applications, such as bone engineering. The decrease in
TSG-6 expression between 10 and 20 populations doubling sug-
gests that the extensively expanded MSCs from a single “universal
donor” may decrease the effectiveness of the cells in suppressing
sterile inflammation.
The use of TSG-6 expression as a biomarker for the efficacy of
hMSCs in suppressing inflammation in vivo is consistent with
previous observations on the protein (10, 12–15). TSG-6 is
a naturally occurring protein of 35 kDa that is secreted by most
cells in response to proinflammatory cytokines, and it has mul-
tiple actions that are linked to modulation of inflammation and
stabilization of the extracellular matrix (12–14). Among its
multiple actions is that TSG-6, either directly or through a
complex with hyaluronan, binds to CD44 on resident macro-
phages in a manner that decreases TLR/NF-κB signaling and
modulates the initial phase of the inflammatory response of most
tissues (11, 20). hMSCs were observed to lose their effectiveness
in several animal models for human diseases after siRNAs were
used to knock down expression of TSG-6 (9–11, 20, 34). Also,
administration of recombinant TSG-6 reproduced most of the
beneficial effects of the hMSCs (9–11, 20, 34). The role of TSG-6
in the cornea model was further validated here by the demon-
stration that overexpression of TSG-6 greatly enhanced the
effectiveness of hMSCs. However, the data to date have not
established that TSG-6 is the only paracrine factor secreted by
MSCs that suppresses inflammation, and it is possible that genes
expressed upstream of TSG-6 may prove to be useful biomarkers.
Surprisingly, comparison of hMSCs from a small cohort sug-
gested that hMSCs from female donors compared with male
donors were more effective in suppressing inflammation in the
cornea model, expressed higher levels of TSG-6, and had slightly
less potential for osteogenic differentiation. The data suggesting
a sex bias in donors of hMSCs is consistent with a large body of
literature demonstrating marked differences in susceptibility to
diseases between men and women (35) and the effects of men-
strual cycles on women (36, 37).
The use of TSG-6 expression as a biomarker should improve
selection of the most effective MSCs for clinical trials and
overcome some of the variations in patient responses.
Materials and Methods
Cell Preparations. hMSCs were prepared from bone-marrow aspirates under
the Institutional Biosafety Committee as previously described (9, 11). The
aspirates were obtained under institutional review board approved proto-
cols over several years from normal volunteers who responded to local
postings in an academic setting (Table S2) and who were screened before-
hand with blood assays for infectious agents. In brief, mononuclear cells
were isolated by ficoll gradient separation of bone-marrow aspirates from
the iliac crest of normal volunteers, incubated in complete culture medium
(CCM) [α-MEM (Life Technologies) containing 17% (vol/vol) FBS (Atlanta
Biologicals), 2 mM L-glutamine, and 1% (vol/vol) penicillin–streptomycin (Life
Technologies)] at high density to obtain adherent cells (P0 cells), replated at
low density (60–100 cells per cm2), incubated to about 70% confluency (cell
density about 10,000 cells per cm2 at harvest), and frozen (P1 cells, 1 × 106
cells per vial). Frozen vials of P1 cells were thawed and incubated at high
density for 24 h to obtain adherent viable cells, replated at low density (200
cells per cm2), and incubated to about 70% confluency (cell density about
10,000 cells per cm2 at harvest) to obtain P2 hMSCs that we used for the
experiments. Population doublings were estimated as an average of five
doublings (50-fold increase in cell number) per passage.
To activate the cells to express TSG-6, P2 hMSCswere incubatedwith 5 ng/mL
TNF-α (R&D Systems) in α-MEM containing 2% FBS for 16 h (9). Similar results
were obtained with two or more vials of P1 hMSCs from the same master
bank prepared from the same donor. The FBS used for the experiments was
selected by screening four to five lots for rapid growth of hMSCs. Different
lots standardized to provide about the same propagation rate of hMSCs
were used to prepare P0 hMSCs, but the same lot was used to expand P1-to-
P2 hMSCs for the experiments here.
RNA Extraction from Cultured Cells and Real-Time RT-PCR Analysis. Total RNA
from monolayer cells was extracted (RNeasy Mini kit; Qiagen), and about
0.1–1 μg of total RNA per sample was used to synthesize double-stranded
cDNA by reverse transcription (SuperScript III; Life Technologies). Real-time
RT-PCR was performed in triplicate for human GAPDH, TSG-6 (TNFAIP6),
HMOX1, COX2, IL1Ra, TGF-β1, IDO1, and TNFRSF1A, using TaqMan Gene
Expression Assays (Life Technologies). Real-time amplification was per-
formed with TaqMan Universal PCR Master Mix (Life Technologies) and
analyzed on a 7900HT fast real-time PCR system (Life Technologies). For
assays, reactions were incubated at 50 °C for 2 min, 95 °C for 10 min, and
then 40 cycles at 95 °C for 15 s, followed by 60 °C for 1 min. Data were
analyzed with Sequence Detection Software, version 2.3 (Life Technologies),
and relative quantities (RQs) were calculated with the comparative CT
method using RQ Manager, version 1.2 (Life Technologies).
Animals. The experimental protocols were approved by the Institutional
Animal Care and Use Committee of the Texas A&M Health Science Center.
Six- to seven-week-old male BALB/c mice (BALB/cAnNCrl; Charles River
Laboratories International) were used in all experiments.
Animal Model of Corneal Injury and Treatment. Chemical burned corneal injury
was produced as described previously (15). Mice were anesthetized by iso-
flurane inhalation. To create the chemical burn, 100% ethanol (Sigma-
Aldrich) was applied to the whole cornea, including the limbus, for 30 s,
followed by rinsing with 1 mL of PBS (Life Technologies). Then, the epithelium
over the whole corneal and limbal region was mechanically scraped using
a surgical blade. Upon completion of the procedure, the eyelids of a mice
were closed with one 8-0 silk suture at the lateral third of the lid margin.
Immediately after injury, mice received i.v. injection of hMSCs (1 × 106) in 0.1
mL of Hanks’ balanced salt solution (HBSS; Life Technologies).
Ocular Surface Evaluation. After injury and treatment, the mouse corneas
were examined for corneal opacity and photographed at 3 d or 7 d. Corneal
opacity was assessed and graded as described previously from the photo-
graphs by an ophthalmologist who was not aware of the treatment of the
mice (15).
Protein Extraction from Cornea. Corneas were excised by cutting just beyond
the limbus, the interior surface was scraped with a small sponge to remove
endothelial cells and iris, and then the corneas were cooled with liquid ni-
trogen. A 3-mm punch was used to obtain a sample from the center of each
cornea that was lysed in 150 μL of tissue-extraction reagent containing
protease inhibitors (Life Technologies). The samples were sonicated on ice
and centrifuged at 15,000 × g at 4 °C for 15 min. The supernatant was used
for MPO ELISAs.
Mouse Model of Peritonitis and Measurements of Inflammation. To induce
inflammation in male BALB/c mice, 1 mL of zymosan solution (1 mg/mL;
Sigma-Aldrich) was administered by i.p, followed by i.p. injection of 1.5 × 106
each donor-derived hMSCs 15 min later (11). After 4 h, inflammatory exudates
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were collected by peritoneal lavage, and the cell-free supernatant was used
to measure levels of the proinflammatory molecules [mouse Tumor necrosis
factor alpha (mTNFα), mouse chemokine (C-X-C motif) ligand 1 (mCXCL1),
mouse Chemokine (C-X-C motif) ligand 2 (mCXCL2)] by ELISAs.
Mouse Model of Lung Injury Induced with Bleomycin. Lung injury was induced
in female C57BL/6J mice anesthetized with isoflurane by administration of
bleomycin sulfate (Sigma-Aldrich) at 2.25 U/kg of body weight in 0.9% so-
dium chloride via an intubation technique (26). Sham animals were given
0.9% sodium chloride alone. Intravenous administration of each donor-
derived hMSCs (2.5 × 105 cells in 150 μL) was performed on days 1 and 4
postinjury. A portable mouse pulse oximeter (STARR Life Sciences Corp.) was
used to monitor arterial blood oxygen saturation (SpO2) in free-roaming
nonanesthetized mice. Weight and SpO2 measurements were recorded
every other day for the entire duration of the 21-d survival study.
ELISAs. Mouse MPO (mouse MPO ELISA kit; HyCult Biotech), TNF-α, CXCL1,
and CXCL2 (R&D Systems) were detected with commercially available ELISA
kits following procedures described by the manufacturers.
TSG-6 Overexpression. To prepare TSG-6 cDNA, total RNA was isolated from
hMSCs that were stimulated by incubation with 5 ng/mL TNF-α in α-MEM
containing 2% FBS overnight (9). About 1 μg of total RNA was used to
produce the first-strand cDNA pool by Reverse Transcriptase (Superscript
II/oligo dT12-18; Life Technologies). cDNAs encoding human TSG-6 (Gen-
Bank accession no. NM_007115) was amplified by PCR using the following
primers: 5′-CGGGGTACCATGATCATCTTAATTTACTT-3′ (sense for hTSG-6),
and 5′-GGTGATCAGTGGCTAAATCTTCCA-3′ (antisense for hTSG-6-WT).
The PCR products were subcloned into the BamHI and EcoRI sites in
multicloning sites of a pEF4-Myc/His plasmid (Life Technologies), and the
plasmids were amplified in Escherichia coli DH5α cells (Life Technologies).
The TSG-6 or control plasmid (0.1 μg per well in six wells) was transfected
into hMSC with Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s protocol. Twenty-four hours after transfection, the cells were
harvested for assays.
Differentiation Assay. For details on the differentiation assay, see SI Materials
and Methods.
Nuclear Extraction and NF-κB Electrophoretic Mobility-Shift Assay. Cells were
harvested at a density of 10,000 cells per cm2, nuclear fraction was extracted
(Nuclear Extraction Kit; Signosis), and assays for nuclear NF-κB were performed
using EMSA Kit (Signosis) according to the manufacturer’s instructions.
Inhibition of NF-κB Signaling. hMSCs were plated at 10,000 per well in CCM in
six-well plates. To inhibit NF-κB signaling, cells were treated with the NF-κB
inhibitor SN50 (EMD Millipore) in CCM every 2 d for 4 d. Then, the medium
was changed to osteogenic differentiation media. For RT-PCR, cells were
treated with SN50 (50–200 ng/mL) for 24 h in CCM and harvested for RNA
extraction.
Statistical Analyses. Comparisons between two groups were made with the use
of unpaired and two-tailed Student t tests. Comparisons of more than two groups
were evaluated by ANOVA. Survival of mice between groups was compared
using a log-rank (Mantel–Cox) test. P < 0.05 was considered significant.
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